MAXUS Medical Co., Ltd. Founded in 2005, it officially became a subsidiary of icares nano medical materials, an OTC listed company in Taiwan in 2019, mainly engaged in research, development, production and sales of high-level ophthalmic medical devices in China.（Hereinafter referred to as MAXUS Medical Co., Ltd.）
 
MAXUS Medical Co., Ltd. It focuses on the intraocular lens and surgical accessories for cataract surgery. With mature manufacturing technology of hydrophobic intraocular lens, hydrophobic intraocular lens with single focus aspheric surface and blue light filtering has been successfully developed. The technical performance of the product is comparable to the international advanced level. Based on the current production platform, a number of high-level functional intraocular lens series products, such as astigmatism correction, multi focus and adjustable products, will be continuously developed in the future。
 
At the same time, we introduce the special high-level surface lubrication technology of medical materials from American affiliated companies, combine with the professional personnel of domestic institutional design, and devote ourselves to the development of the intraocular lens injector. The pre installed intraocular lens is the trend of the future intraocular lens products. It is a product that has pre installed the intraocular lens in the injector, which is not only convenient to use, but also can reduce the risk of pollution during the operation，is MAXUS Medical Co., Ltd. key development project。
 
MAXUS Medical Co., Ltd. Adhering to the concept of "the world in your eyes, let's realize it for you", we are committed to the innovation in the field of high-level ophthalmic medical devices and the development of special instruments for cataract surgery. We hope to strive to provide high-quality products and services for Chinese patients, and at the same time, we are committed to continuously introducing the latest research and development and production technology and the most advanced products into China.